TY  - JOUR
AU  - Rizvi, Naiyer A
AU  - Cho, Byoung Chul
AU  - Reinmuth, Niels
AU  - Lee, Ki Hyeong
AU  - Luft, Alexander
AU  - Ahn, Myung-Ju
AU  - van-den-Heuvel, Michel M
AU  - Cobo, Manuel
AU  - Vicente, David
AU  - Smolin, Alexey
AU  - Moiseyenko, Vladimir
AU  - Antonia, Scott J
AU  - Le-Moulec, Sylvestre
AU  - Robinet, Gilles
AU  - Natale, Ronald
AU  - Schneider, Jeffrey
AU  - Shepherd, Frances A
AU  - Geater, Sarayut Lucien
AU  - Garon, Edward B
AU  - Kim, Edward S
AU  - Goldberg, Sarah B
AU  - Nakagawa, Kazuhiko
AU  - Raja, Rajiv
AU  - Higgs, Brandon W
AU  - Boothman, Anne-Marie
AU  - Zhao, Luping
AU  - Scheuring, Urban
AU  - Stockman, Paul K
AU  - Chand, Vikram K
AU  - Peters, Solange
PY  - 2020
DO  - 10.1001/jamaoncol.2020.0237
UR  - http://hdl.handle.net/10668/15348
T2  - JAMA oncology
AB  - Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small cell lung cancer....
LA  - en
PB  - American Medical Association
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents, Immunological
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
TI  - Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
TY  - research article
VL  - 6
ER  -